基于人群的研究确定儿童高级别脑干胶质瘤癌症特异性死亡和生存的预测因素
该研究利用SEER数据库纳入154例组织学确诊的儿童高级别脑干胶质瘤患者(间变性星形细胞瘤72例,胶质母细胞瘤82例),中位生存期10.0个月。胶质母细胞瘤组织学、发育阶段和大肿瘤体积与癌症特异性死亡显著相关;放疗与6个月和9个月生存改善相关,但与1年及2年生存无关。
要点
- 儿童高级别脑干胶质瘤总体中位生存期10.0个月,2年生存率20%。
- 胶质母细胞瘤组织学与6个月、9个月、1年和2年生存恶化相关。
- 放疗与6个月和9个月生存改善相关,但与1年及2年生存无关。
核心结论
- 胶质母细胞瘤组织学与儿童高级别脑干胶质瘤不良预后相关。
- 无论组织学类型如何,放疗改善6个月和9个月生存,但不改善长期生存。
研究设计与样本
- 利用SEER数据库进行的基于人群的研究。
- 纳入154例组织学确诊的儿童高级别脑干胶质瘤患者,其中间变性星形细胞瘤72例(47%),胶质母细胞瘤82例(53%)。
- 采用多变量分析纳入患者人口学、肿瘤特征和治疗,确定6个月、9个月、1年和2年癌症特异性死亡和生存的预测因素。
主要发现
- 整个队列中位生存期为10.0个月。
- 6个月、9个月、1年和2年生存率分别为75%、57%、42%和20%。
- 胶质母细胞瘤组织学与6个月生存恶化相关(OR 0.19;P=0.0081),9个月(OR 0.18;P<0.001),1年(OR 0.19;P<0.001),2年(OR 0.14;P=0.0055)。
- 放疗与6个月生存改善相关(OR 8.53;P=0.0012)和9个月生存改善相关(OR 3.58;P=0.035),但与1年或2年生存无关。
- 在胶质母细胞瘤中,放疗与生存改善相关(9.0个月 vs 3.0个月;P<0.001)。
关键数值与推荐
- 胶质母细胞瘤组织学、发育阶段和大肿瘤体积与癌症特异性死亡显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pediatric high-grade brainstem gliomas are aggressive tumors with dismal prognoses. Large-scale studies are needed to further characterize these tumors and determine factors influencing cancer-specific mortality and survival at varying time points. METHODS: We used the SEER (Surveillance Epidemiology and End Results) database to conduct a population-based study of pediatric patients with histologically confirmed anaplastic astrocytoma or glioblastoma tumors located within the brainstem. Multivariate analyses incorporating patient demographics, tumor characteristics, and treatments were used to determine predictors of cancer-specific mortality and survival at 6 months, 9 months, 1 year, and 2 years. RESULTS: We included 154 patients from the SEER database: 72 patients with anaplastic astrocytoma (47%) and 82 (53%) with glioblastoma. Median survival for the entire cohort was 10.0 months. Glioblastoma histology, developmental stage, and large tumor size were significantly associated with cancer-specific mortality. Six-month, 9-month, 1-year, and 2-year survival was 75%, 57%, 42%, and 20%, respectively. Glioblastoma histology was associated with worsened survival at 6 months (odds ratio [OR], 0.19; P = 0.0081), 9 months (OR, 0.18; P < 0.001), 1 year (OR, 0.19; P < 0.001), and 2 years (OR, 0.14; P = 0.0055). Radiation therapy was associated with improved survival at 6 (OR, 8.53; P = 0.0012) and 9 months (OR, 3.58; P = 0.035) but not at 1 or 2 years. Radiation therapy was associated with improved survival in glioblastoma (9.0 vs. 3.0 months; P < 0.001). CONCLUSIONS: This population-based study showed that glioblastoma histology is associated with a poor prognosis in pediatric patients with high-grade brainstem gliomas. Regardless of histology, radiation therapy improved survival at 6 and 9 months but not long-term.
引用
- Maxwell R, Luksik AS, Garzon-Muvdi T, et al. Population-based Study Determining Predictors of Cancer-Specific Mortality and Survival in Pediatric High-grade Brainstem Glioma. World Neurosurg. 2018. PMID: 30138731. doi:10.1016/j.wneu.2018.08.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。